Sungen: Bispecific Antibody, Bispecific Antibody Companies

Sungen Biomedical was founded in 2019 which is an innovative antibody drug research and development enterprise incubated by Hotgen Biotech (SH688068), a listed company on the Shanghai Stock Exchange. The co-founder of Sungen Biomedical is Professor Zhiwei Sun, Vice Chairman of China Monoclonal Antibody Industry Committee.

Learn More About Us 

What Does Sungen Achieve?

Sungen Biomedical, founded in 2019 and incubated by Hotgen Biotech, specializes in innovative antibody drugs and large molecule biopharmaceuticals. With a robust R&D pipelines, cutting-edge technology platforms, and strategic collaborations, we are committed to advancing medical science and improving patient outcomes globally.

Explore Sungen Research Innovation 

Technological Platforms

Innovation Achievements

Scientific Frontiers

Sungen News

View all articles 

Oct

AI in Antibody Discovery

The pharmaceutical industry is experiencing a transformative shift, driven by AI-based drug discovery in the realm of biologics. Biologics, complex therapies derived from living organisms, hold immens...

Read article >

Oct

Quality Assurance and Quality Control in Pharmaceutical Company

Within the pharmaceutical industry, quality assurance and quality control are terms often used interchangeably because both are integral to quality management and fulfilling customer expectations. The...

Read article >

Oct

Monoclonal vs. Bispecific Antibodies

In the rapidly evolving world of biotechnology, antibodies have become powerhouse tools in fighting diseases like cancer, autoimmune disorders, and infections. But what sets monoclonal antibodies (mAb...

Read article >